← All C4 Therapeutics, INC filings

C4 Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
CCCC
C4 Therapeutics, INC
DEF: C4 Therapeutics Schedules 2026 Annual Meeting
C4 Therapeutics announces its 2026 Annual Meeting of Stockholders, set for June 24, 2026, to elect directors, vote on executive compensation, ratify auditors, and approve a plan amendment.
NASDAQ
CCCC
C4 Therapeutics, INC
DEFA14A: C4 Therapeutics, Inc. Files Definitive Proxy Statement
C4 Therapeutics, Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.
NASDAQ
CCCC
C4 Therapeutics, INC
DEF: C4 Therapeutics Seeks Stockholder Approval for Increased Share Authorization and Executive Compensation
C4 Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, approve executive compensation, ratify the appointment of KPMG LLP, and increase the number of authorized shares of common stock.
NASDAQ
CCCC
C4 Therapeutics, INC
DEFA14A: C4 Therapeutics Files Definitive Proxy Statement
C4 Therapeutics has filed a definitive proxy statement with the SEC, indicating preparations for an upcoming shareholder meeting.
NASDAQ
CCCC
C4 Therapeutics, INC
DEF 14A: C4 Therapeutics Seeks Stockholder Approval for Director Elections, Executive Pay, and Auditor Ratification at 2024 Annual Meeting
C4 Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 20, 2024, to vote on director elections, executive compensation, and the ratification of its independent auditor.